Literature DB >> 26036427

Hysteroscopy and heavy menstrual bleeding (to cover TCRE and second-generation endometrial ablation).

M Y Bongers1.   

Abstract

Endometrial resection and ablation are an intermediate treatment for heavy menstrual bleeding (HMB). Many women do not like the continuous use of hormones, nor do they prefer a rigorous treatment as hysterectomy. The first generation of endometrial resection/ablation is now superseded by the second-generation endometrial ablation. Both seem to be equally effective in reducing HMB, and there was no evidence that rates of satisfaction differed significantly. Overall, second-generation techniques were often easier to perform with shorter surgery times and the ability to use local rather than general anaesthesia. Complications seem to be less after second-generation endometrial ablation; however, the easiness of use can be a pitfall. Prognostic parameters should be taken into account while counselling women who opt for an endometrial ablation. The most important prognostic parameters are age (satisfaction increases with age) and preoperative dysmenorrhoea (decreases satisfaction).
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  endometrial ablation; first-generation endometrial ablation; heavy menstrual bleeding; prognostic parameters; second-generation endometrial ablation

Mesh:

Year:  2015        PMID: 26036427     DOI: 10.1016/j.bpobgyn.2015.03.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  2 in total

1.  Comparison of Bipolar Ball Endometrial Ablation and Transcervical Resection of the Endometrium in the Treatment of Heavy Menstrual Bleeding: A Randomized Clinical Trial.

Authors:  Murali Subbaiah; Neethu Selvest; Dilip Kumar Maurya
Journal:  Gynecol Minim Invasive Ther       Date:  2021-08-03

2.  Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation.

Authors:  Hui Xie; Yajun Wan; Shuijing Yi; Fei Zeng; Xin Sun; Yimin Yang; Songshu Xiao
Journal:  Int J Gynaecol Obstet       Date:  2021-11-16       Impact factor: 4.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.